Adjuvant imatinib therapy for gastrointestinal stromal tumors

Peter W T Pisters; Chiara Colombo

doi:10.1002/jso.22002

Adjuvant imatinib therapy for gastrointestinal stromal tumors

Peter W T Pisters, Chiara Colombo

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Surgery is the standard of care for primary resectable gastrointestinal stromal tumors (GISTs), but half of surgically treated patients relapse. Imatinib (IM) has been shown to prolong recurrence-free survival after complete surgery and is now approved as adjuvant therapy (400 mg/day) for high-risk GIST patients. IM is well tolerated, with mild to moderate side effects observed. Whether adjuvant IM prolongs overall survival is under evaluation in two ongoing clinical trials. J. Surg. Oncol. 2011; 104:896-900.

Original language	English
Pages (from-to)	896-900
Number of pages	5
Journal	Journal of Surgical Oncology
Volume	104
Issue number	8
DOIs	https://doi.org/10.1002/jso.22002
Publication status	Published - Dec 2011

Keywords

adjuvant therapy
adverse events
gastrointestinal stromal tumor
GIST
imatinib
risk stratification

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.22002

Fingerprint Dive into the research topics of 'Adjuvant imatinib therapy for gastrointestinal stromal tumors'. Together they form a unique fingerprint.

Cite this

@article{e08337b8e32c45db8287497f0c6a9ecd,

title = "Adjuvant imatinib therapy for gastrointestinal stromal tumors",

abstract = "Surgery is the standard of care for primary resectable gastrointestinal stromal tumors (GISTs), but half of surgically treated patients relapse. Imatinib (IM) has been shown to prolong recurrence-free survival after complete surgery and is now approved as adjuvant therapy (400 mg/day) for high-risk GIST patients. IM is well tolerated, with mild to moderate side effects observed. Whether adjuvant IM prolongs overall survival is under evaluation in two ongoing clinical trials. J. Surg. Oncol. 2011; 104:896-900.",

keywords = "adjuvant therapy, adverse events, gastrointestinal stromal tumor, GIST, imatinib, risk stratification",

author = "Pisters, {Peter W T} and Chiara Colombo",

year = "2011",

month = dec,

doi = "10.1002/jso.22002",

language = "English",

volume = "104",

pages = "896--900",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Adjuvant imatinib therapy for gastrointestinal stromal tumors

AU - Pisters, Peter W T

AU - Colombo, Chiara

PY - 2011/12

Y1 - 2011/12

N2 - Surgery is the standard of care for primary resectable gastrointestinal stromal tumors (GISTs), but half of surgically treated patients relapse. Imatinib (IM) has been shown to prolong recurrence-free survival after complete surgery and is now approved as adjuvant therapy (400 mg/day) for high-risk GIST patients. IM is well tolerated, with mild to moderate side effects observed. Whether adjuvant IM prolongs overall survival is under evaluation in two ongoing clinical trials. J. Surg. Oncol. 2011; 104:896-900.

AB - Surgery is the standard of care for primary resectable gastrointestinal stromal tumors (GISTs), but half of surgically treated patients relapse. Imatinib (IM) has been shown to prolong recurrence-free survival after complete surgery and is now approved as adjuvant therapy (400 mg/day) for high-risk GIST patients. IM is well tolerated, with mild to moderate side effects observed. Whether adjuvant IM prolongs overall survival is under evaluation in two ongoing clinical trials. J. Surg. Oncol. 2011; 104:896-900.

KW - adjuvant therapy

KW - adverse events

KW - gastrointestinal stromal tumor

KW - GIST

KW - imatinib

KW - risk stratification

UR - http://www.scopus.com/inward/record.url?scp=80855139422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855139422&partnerID=8YFLogxK

U2 - 10.1002/jso.22002

DO - 10.1002/jso.22002

M3 - Article

C2 - 22069174

AN - SCOPUS:80855139422

VL - 104

SP - 896

EP - 900

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 8

ER -